Novartis eyecare subsidiary Alcon has agreed to acquire the Institut Mérieux, Ascension Health and MemorialCare Health System-backed MIGS technology provider.

Alcon, a vision care subsidiary of pharmaceutical group Novartis, agreed on Monday to acquire Ivantis, a US-based, corporate-backed minimally invasive glaucoma surgery (MIGS) technology provider, for $475m.

The deal could be boosted by potential regulatory and commercial milestone payments, and is expected to close by the end of the first quarter of 2022.

Ivantis provides a device called Hydrus Microstent which is designed to help ophthalmic surgeons conduct MIGS procedures to treat glaucoma, which is caused by increased pressure in…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
Email LinkedIn